Moderna, Inc. (NASDAQ:MRNA) Given Consensus Rating of “Hold” by Brokerages

Shares of Moderna, Inc. (NASDAQ:MRNA) have been assigned an average recommendation of “Hold” from the twenty-two ratings firms that are presently covering the stock, MarketBeat reports. Four equities research analysts have rated the stock with a sell recommendation, twelve have issued a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $79.50.

MRNA has been the topic of a number of research analyst reports. Argus lowered Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Sanford C. Bernstein initiated coverage on Moderna in a research note on Thursday, October 17th. They issued a “market perform” rating and a $55.00 price target on the stock. JPMorgan Chase & Co. lowered their price target on Moderna from $59.00 to $45.00 and set an “underweight” rating on the stock in a research note on Tuesday, November 26th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $75.00 price target on shares of Moderna in a research note on Thursday, September 19th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $69.00 price target (down from $115.00) on shares of Moderna in a research note on Monday, November 18th.

Insider Activity

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now owns 19,717 shares of the company’s stock, valued at $843,690.43. This represents a 6.71 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 2,664 shares of company stock valued at $115,210 in the last quarter. Insiders own 15.70% of the company’s stock.

Institutional Investors Weigh In On Moderna

Several institutional investors and hedge funds have recently modified their holdings of the company. State Street Corp raised its holdings in shares of Moderna by 12.1% in the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after buying an additional 1,823,276 shares during the period. Geode Capital Management LLC raised its holdings in shares of Moderna by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock valued at $470,670,000 after buying an additional 178,115 shares during the period. Wellington Management Group LLP raised its holdings in shares of Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after buying an additional 906,114 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Moderna by 0.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock valued at $260,023,000 after buying an additional 19,819 shares during the period. Finally, The Manufacturers Life Insurance Company increased its holdings in Moderna by 6.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock worth $205,431,000 after purchasing an additional 178,939 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Stock Up 0.9 %

Moderna stock opened at $42.57 on Tuesday. The stock has a market capitalization of $16.38 billion, a PE ratio of -7.31 and a beta of 1.60. Moderna has a 12 month low of $35.80 and a 12 month high of $170.47. The business has a 50 day simple moving average of $43.38 and a 200-day simple moving average of $71.48. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. The business had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business’s revenue was up 3.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.39) earnings per share. On average, analysts anticipate that Moderna will post -9.3 EPS for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.